Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

66.12
+1.051.61%
Post-market: 65.50-0.6200-0.94%18:48 EDT
Volume:1.36M
Turnover:89.66M
Market Cap:12.78B
PE:174.47
High:66.36
Open:65.03
Low:65.02
Close:65.07
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.75
T/O Rate:0.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.02
PE(LYR):36.73

Loading ...

BioMarin and n-Lorem Foundation enter research collaboration in ReNU syndrome

TIPRANKS
·
Jul 27

Biomarin Pharmaceutical - and N-Lorem Announce Global Exclusive License to Develop Aso Medicine for Renu Syndrome

THOMSON REUTERS
·
Jul 27

BioMarin, n-Lorem Partner to Develop Antisense Drug Candidate for ReNU Syndrome

Reuters
·
Jul 27

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

Reuters
·
Jul 27

Biomarin Pharmaceutical is Maintained at Buy by Citigroup

Dow Jones
·
Jul 17

FDA Accepts Biomarin Voxzogo Full-approval Application for Children with Achondroplasia

Reuters
·
Jul 13

U.S. Food and Drug Administration Accepts Biomarin's Supplemental New Drug Application for Full Approval of Voxzogo® (vosoritide) for Children with Achondroplasia

THOMSON REUTERS
·
Jul 13

Biomarin Pharmaceutical - FDA Sets Pdufa Target Action Date of Feb. 28, 2027 for Voxzogo Snda

THOMSON REUTERS
·
Jul 13

Is BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?

Simply Wall St.
·
Jul 08

Biomarin Pharmaceutical is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Jul 08

Jefferies Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Jul 06

Spruce Biosciences names Agnieszka Jurecka vice president, medical affairs

Reuters
·
Jun 22

H.C. Wainwright Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Jun 22

BioMarin’s IMPALA Study Aims to Boost Palynziq Value With Better Tolerability

TIPRANKS
·
Jun 18

BioMarin Pharmaceutical Presents 3-Year Voxzogo Data, Early BMN 333 Results for Growth Disorder Treatments

MT Newswires Live
·
Jun 16

BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia

TIPRANKS
·
Jun 16

BioMarin says VOXZOGO lifts height SDS 0.72 over three years in hypochondroplasia study at ENDO 2026

Reuters
·
Jun 16

Is VOXZOGO’s Hypochondroplasia Data and Amicus Deal Reshaping the Investment Case for BioMarin (BMRN)?

Simply Wall St.
·
Jun 10

BioMarin shareholders approved 7,650,000-share increase to 2017 equity plan at annual meeting

Reuters
·
Jun 05

A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Strength

Simply Wall St.
·
Jun 04